Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women

Trial Profile

Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms VOICE
  • Most Recent Events

    • 26 Apr 2022 Results of a pooled participant-level data analysis ((iPrEx, VOICE and Partners PrEP studies) characterizing HIV-preventive, plasma tenofovir concentrations published in the Clinical Infectious Diseases
    • 16 Feb 2022 Results assessing vaginal proteins that associate with HIV acquisition in women enrolled in the VOICE trial presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 24 Aug 2020 Results of a comprehensive model analysis using data from following clinical studies: HPTN082, VOICE trial, HPTN035, FEM-PrEP, ASPIRE, ECHO trials for estimation of HIV incidences and interventions effectiveness published in the JAIDS
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top